EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-05-26
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 180
- Registration Number
- NCT01360840
- Locations
- 🇫🇷
Hôpitaux Civils de Colmar-CH Louis Pasteur, Colmar, France
🇫🇷Institute Gustave Roussy, Villejuif, France
🇷🇺Budzhet Clinical Oncology Center, Izhevsk, Russian Federation
Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study
- First Posted Date
- 2010-11-09
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 59
- Registration Number
- NCT01237340
Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2016-07-12
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 340
- Registration Number
- NCT01226745
- Locations
- 🇺🇸
Aurora Clinical Site 132, Aurora, Colorado, United States
🇺🇸Ormond Beach Clinical Site 129, Ormond Beach, Florida, United States
🇺🇸Sarasota Clinical Site 116, Sarasota, Florida, United States
Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 307
- Registration Number
- NCT01207648
- Locations
- 🇻🇪
Research Site, Maracaibo, Venezuela
An Open Label, Canadian Phase IIIb Study With Ovidrel in Ovulation Induction (OI) and Assisted Reproductive Technique (ART)
Completed
- Conditions
- First Posted Date
- 2010-06-29
- Last Posted Date
- 2013-08-06
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 3
- Registration Number
- NCT01152866
A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies
Phase 3
Completed
- Conditions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 55
- Registration Number
- NCT01121991
First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 38
- Registration Number
- NCT01110083
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 38
- Registration Number
- NCT01085318
- Locations
- 🇺🇸
EMD Serono, Inc., Rockland, Massachusetts, United States
MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 16
- Registration Number
- NCT01085331
- Locations
- 🇪🇸
Research Site, Barcelona, Spain
A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies
- First Posted Date
- 2010-03-04
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 124
- Registration Number
- NCT01080664
- Locations
- 🇨🇭
Kantonsspital St Gallen, St Gallen, Switzerland
🇺🇸CTRC at the UT Health Science Center at San Antonio, San Antonio, Texas, United States
🇩🇪Technische Universitat Munchen, Munchen, Germany
© Copyright 2024. All Rights Reserved by MedPath